Follow Us:

Institute for OneWorld Health: Strategic Planning

Case Overview

FSG helped the Institute for OneWorld Health develop a five-year diarrheal disease program strategy and access plan based on in-depth research in three countries.

The Challenge

Diarrheal diseases cause over 2,000,000 deaths a year worldwide, mostly affecting children under age five. OneWorld Health has distinguished itself as a leader in the international health field since its founding in 2000. OneWorld Health selected diarrhea as a new area of focus and engaged FSG to develop an access strategy for new products and a 5-year plan to communicate how the diarrheal disease portfolio would evolve. Specifically, the plan addressed on what specific etiologies of diarrheal disease the organization would focus, how it would manage a portfolio of products, and how the products would be made available through a mix of private and public sector channels.

Approach & Solutions

FSG began by examining the history of the oral re-hydration solutions and zinc uptake in the developing world. The team conducted a thorough literature review and held interviews with leading experts in diarrheal disease. Interviews focused on understanding lessons from past efforts to promote the use of oral re-hydration solutions, one of the most effective and underutilized tools available to promote child health. Zinc supplementation, another newly identified tool in the fight against childhood diarrhea also held learning lessons. FSG’s analysis focused on understanding key factors in supply, demand, and the policy environment that would affect the uptake of potential new therapeutics.

To determine opportunities for impact, we worked with OneWorld Health to develop a hypothetical product profile, while gathering feedback from policymakers, providers, researchers, patients, and child health advocates to determine the most important features of a new product.

FSG conducted secondary research assessing both the potential for health impact and potential for revenue generation of the product in India (Delhi, West Bengal and Uttar Pradesh), Pakistan, and Peru. We assessed the intended health impact and identified patient needs for each potential causative agent, and obtained sales data for competitive products. FSG researched potential manufacturing partners, dynamics of the private sector, access distribution channels, and pricing strategies.

A set of opportunities were developed through this process and shared with OneWorld Health at a scientific advisory board meeting facilitated by FSG in London. FSG worked closely with the advisory board to articulate a set of priorities for the future portfolio. Our research validated an opportunity to test and develop new products for persistent diarrhea within the context of existing products in the marketplace. The research highlighted the challenges of marketing new products, and the opportunity to engage the strong private sector in India. Based on FSG’s recommendations, OneWorld Health also moved from a single-product focus to a portfolio approach to product development.

About Institute for OneWorld Health

The mission of Institute for OneWorld Health is “to develop safe, effective and affordable new medicines for people with infectious diseases in the developing world.” The organization’s vision is to “serve as a positive agent for change by saving lives, improving health and fulfilling the promise of medicine for those most in need.”

Follow Us:

Facebook Twitter YouTube LinkedIn RSS